Denali Therapeutics initiates dosing in Phase 1b study of DNL201

Denali Therapeutics announced initiation of dosing in a Phase 1b clinical study of DNL201 in patients with Parkinson’s disease. DNL201, Denali’s lead LRRK2 therapeutic candidate, is a small molecule inhibitor of leucine-rich repeat kinase 2, or LRRK2. LRRK2 is a regulator of lysosomal function, which is impaired in Parkinson’s disease and may be restored by LRRK2 inhibition. Inhibition of LRRK2 activity may potentially slow the progression of disease in patients with a genetic LRRK2 mutation as well as in patients with sporadic Parkinson’s disease.
https://thefly.com/landingPageNews.php?id=2834579